Abstract: The present invention relates to soluble SIRP? binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble SIRP? binding protein comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first monovalent single chain polypeptide comprising a first SIRP? binding domain fused at the N-terminal part of a heavy chain constant region of an antibody; and, (ii) a second monovalent single chain polypeptide comprising a second SIR % binding domain fused at the N-terminal part of a CL light chain constant region of an antibody. The invention further relates to soluble SIRP-binding antibody-like protein as shown in FIG. 1.

Abstract: The present invention relates to soluble CD47 binding polypeptides, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble CD47 binding polypeptide for use as a medicament, comprising an extracellular domain of SIRP? (CD172a) or functional derivatives which bind to human CD47.